# Cetuximab as Therapy for Recurrent Non-Small Cell Lung Cancer Patients Who Have Received Prior Therapy

> **NCT00694603** · PHASE2 · TERMINATED · sponsor: **Lecia V. Sequist** · enrollment: 56 (actual)

## Conditions studied

- Non-small Cell Lung Cancer

## Interventions

- **DRUG:** Cetuximab

## Key facts

- **NCT ID:** NCT00694603
- **Lead sponsor:** Lecia V. Sequist
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-09
- **Primary completion:** 2009-09
- **Final completion:** 2009-09
- **Target enrollment:** 56 (ACTUAL)
- **Why stopped:** Slow accrual
- **Last updated:** 2012-09-06

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00694603

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00694603, "Cetuximab as Therapy for Recurrent Non-Small Cell Lung Cancer Patients Who Have Received Prior Therapy". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00694603. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*